https://www.selleckchem.com/products/ab680.html
Background Gestational alloimmune liver disease (GALD) is a rare but critical cause of neonatal liver failure. After discovering the maternal-fetal alloimmune mechanism, intravenous immunoglobulin (IVIG) with or without exchange transfusion (ET) has gradually replaced antioxidant cocktails as the first-line therapy. Whether such therapy changes the outcome of neonates with GALD is yet to be defined. Method We reported a pair of twins with discordant presentations, mild and self-limited in the older, whereas liver failure in the younger, w
Gefällt mir
Kommentar
Teilen
